Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1NET 1Head & Neck 1Gastrointestinal 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Neoplasm Metastasis 5Colorectal Neoplasms 4Solid Tumor 3Stomach Neoplasms 2Melanoma 2Endometrial Neoplasms 2Turcot syndrome 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Rectal Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Metastatic Solid Tumors 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma 1Extensive Stage Small Cell Lung Cancer 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Colonic Neoplasms 1Breast Neoplasms 1Advanced Solid Tumors 1Adenocarcinoma 1

Interventions

fosbretabulin 2Sorafenib 2Paclitaxel 2Doxorubicin 2tislelizumab 1surufatinib 1pegfilgrastim 1lenvatinib 1efatutazone 1combretastatin 1Radiotherapy 1PLX8394 1Magnetic Resonance Spectroscopy 1Imatinib Mesylate 1Fluorodeoxyglucose F18 1Filgrastim 1Cisplatin 1Carboplatin 1CUDC-907 1Bevacizumab 12-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Thyroid Carcinoma, Anaplastic × tislelizumab × Clear all
NCT04579757 2025-05-08

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Hutchmed

Phase 1/2 Terminated
87 enrolled 29 charts
EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡